On Nov. 17, 2022, the U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.ﾠ

Type 1 diabetes is one of the most common chronic diseases of childhood, impacting between one in 300 to one in 600 school-aged children. It’s a lifelong condition that requires constant diet management and insulin therapy. Now, the availability of teplizumab for at-risk patients will help delay the onset of the disease. Herold is excited about the valuable, disease-free years the drug can offer.

Each year, around 30,000 new individuals are diagnosed with type 1 diabetes in the United States. The disease is caused by immune-mediated killing of beta cells. These cells are found in the pancreas and make insulin, which is essential for life. A hundred years ago, before the discovery of insulin in 1922, type 1 diabetes was a lethal diagnosis.